SOURCE: BioMedReports


March 01, 2012 08:59 ET

CEO Says 2012 Promises to Be a New Chapter in the History of EpiCept Corporation

LOS ANGELES, CA--(Marketwire - Mar 1, 2012) - On Wednesday, EpiCept Corporation (OTCQX: EPCT) (PINKSHEETS: EPCT) was among a short list of U.S. companies reported by Bloomberg as having reported positive surprises or matched expectations. This after company officials announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

The Tarrytown, New York-based EpiCept is a specialty pharmaceutical company seeking to address areas of high, unmet medical needs in cancer and pain through its innovative technologies, but it has remained relatively undiscovered by many biotech speculators. That may start to change as investors become increasingly aware of the firm's pipeline and clinical progress achievements.

In an exclusive video interview, Jack V. Talley, Chief Executive Officer, President and Director of EpiCept Corporation tells investors that his firm is breaking new ground with promising results.

"2012 promises to be a new chapter in the history of EpiCept primarily because of the results we've achieved for AmiKet™ in chemotherapy-induced peripheral neuropathy (CPN)," explained Talley. "This gives us the opportunity to invest in a drug for a disease that has a huge unmet medical need and a very reasonable path as well as a time and cost in order to get to a new drug application."

Talley told the markets on Wednesday that one of the firm's most significant milestones was the outcome of their End-of-Phase II meeting with U.S. Regulators at the Food and Drug Administration (FDA) concerning AmiKet™. "We were pleased to receive FDA approval to start Phase III activities and delighted with the encouragement they received from the FDA to file for Fast Track status.

"The granting of Fast Track status should provide us the opportunity to regularly consult with the FDA in order to determine the optimum path towards approval. We believe that the meaningful guidance provided to us by the FDA will positively advance our ongoing discussions with several potential partners," said Talley.

The Company believes that its cash is sufficient to fund operations into the third quarter of 2012. The Company has reduced certain R&D and G&A expenses in 2012 compared with 2011 and raised cash via a repricing of expiring stock purchase warrants in January 2012 and a $2 million registered direct financing in February 2012.

The video interview with Jack V. Talley is now available at:

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556